Phase 1 Trials Of Bharat Biotech's Nasal Vaccine For Covid-19 Now Underway: MD Dr Krishna Ella

Bharat Biotech Managing Director (MD) Dr Krishna Ella has said that the biotechnological company’s nasal vaccine for Covid-19 is currently under its phase 1 trial.

8 May is the deadline fixed for the same and Dr Ella believes that the company could very well become the first in the world to launch a Covid-19 nasal vaccine.

“Injectible vaccines only protect up to lower lung, but the upper lungs and nose are not protected. People vaccinated may get and infection. But the vaccine will prevent you from hospitalisation. You might get a fever for two-three days. But mortality will be reduced,” he was quoted as saying to Republic TV.

Dr Ella said that taking a single dose of the nasal vaccine will help break the chain of transmission and further the process of flattening the curve of Covid-19 infections.

“If you take one dose of nasal vaccine you could block the infection and thereby block the transmission chain and then you can flatten the curve. It is just about four drops like polio, two in one nostril and two in the other. Now global authorities like the WHO are getting convinced about nasal as a second-generation vaccine,” Dr Ella said.